"Metabolic syndrome" — a cluster of obesity, insulin resistance, hypertension, and lipid abnormalities — long positioned obesity as one contributor to a broader web of cardiovascular risk.

Statins became the cornerstone of preventive cardiology decades ago, lowering low-density lipoprotein (LDL) cholesterol and cutting cardiovascular events after entering widespread use.

More recently, GLP-1 receptor agonists have shifted the conversation toward obesity and weight loss itself — somewhat detached from that broader metabolic syndrome framework.

Media coverage of GLP-1 drugs has increasingly focused on their potential as transformative weight-loss treatments, with the drugs becoming unusually prominent in public discussions of metabolic health.

Statins, meanwhile, remain a cornerstone of cardiovascular risk reduction. Current guidelines continue to recommend LDL-lowering therapy according to an individual's cardiovascular risk, including among people with obesity and other metabolic risk factors. As GLP-1-based therapies expand their role in obesity and cardiometabolic disease, understanding how they complement established lipid-lowering approaches remains important.

Could GLP-1 Drugs Challenge Statins in Cardiovascular Prevention? 

The evidence supporting statins for cardiovascular disease prevention through LDL cholesterol lowering has remained consistent over the years. A 2005 meta-analysis of 10 randomized controlled trials encompassing 79,494 patients found that statins reduced major coronary events by 27% and stroke by 18%. Statin use was also associated with a 15% reduction in all-cause mortality.

Roughly two decades later, in 2026, Australian researchers assessed the effectiveness of statins vs placebo for the primary prevention of cardiovascular events. In the randomized study, 4984 patients received atorvastatin and 4987 received placebo. After a median follow-up of 5.9 years, researchers observed 10.9 cardiovascular events per 1000 person-years in the atorvastatin group vs 15.5 per 1000 person-years in the placebo group.

"Statin medications have a long track record of cardiovascular risk reduction," Jorge Moreno, MD, an assistant professor of medicine and obesity medicine specialist at Yale School of Medicine, New Haven, Connecticut, told Medscape Medical News. "I think statins are here to stay and will continue to be used in patients with obesity at high risk for cardiovascular disease."

A broader question is how the cardiovascular benefits of GLP-1-based therapies fit alongside those of statins, particularly given the growing evidence that these drugs can reduce cardiovascular events. 

A 2023 study of 17,604 patients with preexisting cardiovascular disease and a BMI of 27 or greater but without diabetes randomly assigned participants 1:1 to receive once-weekly subcutaneous semaglutide or placebo. Over a mean treatment exposure of 34.2 months, the risk for a composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was 20% lower in the semaglutide group.

In August 2026, the FDA approved tirzepatide for an additional indication: reducing major cardiovascular events in adults with type 2 diabetes at high risk.

Moreno called these developments "excellent" but said statins still play a major role in reducing cardiovascular risk.

"Patients at high risk for cardiovascular disease, including those with elevated cholesterol levels, will still need a statin or other cholesterol-lowering therapy even if they're taking a GLP-1 medication," he said. "Based on the data, I doubt GLP-1s will replace statins; they remain the first-line treatment for cholesterol management and cardiovascular risk reduction."

Assessing Cardiovascular Risk Beyond Weight Loss 

With the popularity of GLP-1 drugs surging worldwide — accounting for nearly 8% of all US prescriptions in March 2026 — many patients with obesity arrive at consultations requesting these medications, according to Jennifer Ng, MD, an internal medicine and primary care physician specializing in obesity medicine at Mount Sinai, New York City. Because of the often substantial weight loss associated with GLP-1s (a landmark study found that once-weekly subcutaneous semaglutide 2.4 mg with lifestyle intervention produced a 14.9% mean weight reduction over 68 weeks), many patients with both obesity and high cholesterol prefer these medications despite their shorter track record compared with statins. 

Some patients also express concern about potential statin side effects, which can include an increased risk for diabetes, liver enzyme elevations, and muscle-related symptoms such as myalgia and myopathy. GLP-1s have their own well-documented side effects, most notably gastrointestinal symptoms such as nausea, vomiting, and diarrhea.

To identify patients who might benefit from statins in addition to GLP-1 therapy, Ng recommends using clinical risk assessment tools such as the American Heart Association (AHA)'s Predicting Risk of Cardiovascular Disease Events (PREVENT) equations. Such tools estimate cardiovascular risk using multiple clinical factors rather than focusing primarily on body weight. For example, a PREVENT score of 10% or greater identifies patients at high cardiovascular risk and can help inform decisions about lipid-lowering therapy.  

Evolving guidelines on lipid management also reflect the expanding evidence base for statins. For example, 2026 guidelines from the AHA, the American College of Cardiology, and other societies explicitly recommend statin therapy for dyslipidemia and cardiovascular risk assessment beginning at age 30 rather than age 40. This change could identify younger, high-risk patients who may benefit from statin therapy.

The Continuing Case for Statins 

While some patients remain skeptical of statins, others enthusiastically advocate for their use as preventive medications even in the absence of a clear indication. This enthusiasm is sometimes seen among patients with a family history of dyslipidemia, as well as those interested in longevity who hope to prevent diseases before they develop. 

Rita Redberg, MD, MS, a cardiologist and professor of medicine at the University of California, San Francisco, does not recommend such an approach. In a 2022 study, she and colleagues outlined how the potential harms of statin therapy could sometimes outweigh the benefits, especially among older adults, and argued that an overemphasis on statins could shift attention away from physical activity and healthy eating, which remain crucial determinants of cardiovascular health.

"I am not a fan of statins for most people in the primary prevention setting, as they don't help people feel better or live longer," she told Medscape Medical News. "I favor treatments that improve meaningful clinical outcomes rather than focusing on lab tests, which are surrogate markers."

GLP-1-based therapies and statins address different, although overlapping, treatment targets: GLP-1 drugs are used primarily for weight management and glycemic control, while statins primarily lower LDL cholesterol and reduce atherosclerotic cardiovascular risk. For many patients, therefore, the therapies may be complementary rather than competing. 

Asked what the public should know about statins, Ng emphasized their established benefits.

"Statins are a great medication. They've been around for a long time, with a lot of evidence behind them," she told Medscape Medical News. "There can be potential side effects, but the same can be said for all medications, and medications can always be changed if they occur."

Moreno, Ng, and Redberg reported having no relevant disclosures. 

Ryner Lai's work examines local and regional health developments within the broader context of global policy trends and emerging ideas. His areas of interest include rare diseases, mental health, and international health policymaking.